Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhin... ( MISSISSAUGA ON span class xn-chro.....)

Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial

Date:3/15/2010

MISSISSAUGA, ON, March 15 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis.

The randomized, double-blind, placebo-controlled, single-centre trial will assess the efficacy and safety of WF10 infusions for the treatment of patients with severe persistent allergic rhinitis. The trial will enroll 50 patients who have at least a two-year history of persistent allergic rhinitis, and who have a positive allergen skin test. The trial's primary endpoint will be the change from patient baseline to final Total Nasal Symptom Score, an established scale to measure the aggregation of symptoms consistent in allergic rhinitis. Furthermore, patients will undergo rhinometric examinations and spirometric tests at baseline and during the assessment period to further evaluate WF10's efficacy.

At the first treatment visit, patients who meet the inclusion and exclusion criteria will be randomized into one of two treatment groups: WF10, or placebo. Treatment will be administered once daily for five consecutive days. Patients will be assessed over a three-month period. Nuvo intends t
'/>"/>

SOURCE Nuvo Research Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Researchers recommend curriculum on unhealthy substance use
2. Using new approach, Mayo Clinic researchers find level of gene alters risk of Alzheimers disease
3. CEMPER.COM Launches New Link Research Tool Version with New Data Source Support for SeoMoz, Sistrix, SEMrush and Majestic SEO
4. Carnegie Mellon research provides insight into brains decision-making process
5. Researchers discover brain tumors grow-or-go switch
6. Get up, get out and go: NC State research tackles childhood obesity
7. A new beat in heart research
8. Harvard School of Public Health unveils comprehensive, public online library of firearms research
9. Penn researcher, Louis J. Soslowsky, PhD, winner of the AAOS Kappa Delta Ann Doner Vaughan Award
10. Research streamlines data processing to solve problems more efficiently
11. Research findings expected to ease treatment of low neutrophil counts in cancer patients

Post Your Comments:

(Date:5/21/2013)... 21, 2013 Dr. Francine Kaufman , inventor ... used with her patients in the 1980s: It weighed several pounds ... the most part, it could only be used in the hospital ... since then, and the advantages are greater as well. The insulin ... of the body, often on a belt or a pocket. It ...

(Date:5/21/2013)... Atlanta, GA (PRWEB) May 21, 2013 ... Care, ScripNet and Procura Management, today announced that ... Award at Catamaran’s client advisory meeting. Conferred ... has partnered with Catamaran to create cutting edge ... This year, Healthcare Solutions was recognized for its ...

(Date:5/21/2013)... Healthcare industry leaders, health information technology startups, and ... Emerging Healthcare Technology Conference, June 10 at the Fluno ... new event is part of the 11th annual Digital ... being held June 10-12 at the Fluno Center for ... for healthcare information technology (IT) grew dramatically in 2012 ...

(Date:5/21/2013)... 21, 2013 Two-thirds of patients who ... lung cancer reported that they engage in at least ... according to new findings from the National Health ... Health . The research will be presented today at ... for Pharmacoeconomics and Outcomes Research) in New Orleans. ...

(Date:5/21/2013)... May 21, 2013 The producers of ... air dates for Peterborough, Ontario, Canada. The area is famous ... for Canadians and Americans. It is located an hour from ... Peterborough is located in the Kawartha Hills, home to several ... economic stability to the area. Residents and visitors to this ...

Breaking Medicine News(10 mins):Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2 Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3 Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4 Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2 Health News:“Start Me Up" Healthcare Conference: Where Healthcare CIOs, Entrepreneurs and Investors Meet 2 Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2 Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3 Health News:Net Worth Business TV Announces May Air Dates for Peterborough, Ontario 2

[0] Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives [0] Healthcare Solutions Receives Innovation Award From Catamaran [0] “Start Me Up" Healthcare Conference: Where Healthcare CIOs, Entrepreneurs and Investors Meet [0] Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research [0] Net Worth Business TV Announces May Air Dates for Peterborough, Ontario

... Annual Dinner, May 17, DETROIT, Jan. 31 ... its nurse paging system, thanks to the,generosity of ... vice,president of development for the Institute., (Logo:, ... our 26th Annual Dinner May 17, Ford Motor ...

... Long-time local partners cite proprietary research, strategic planning and ... superior creative as keys to their success, ... two major,national advertising awards at the Consumer Health World Conference ... have again taken top honors in a national awards program., ...

... once looked at for cancer, also attacks the human immunodeficiency ... research published today online in the open access journal Retrovirology. ... learned to hide out in certain human cells where it ... serve as viral reservoirs. Operating from these havens, the virus ...

... ABAX ), a medical products company manufacturing point-of-care,blood analysis ... 31, 2007., Highlights for the third ... $25.7 million, up 17% over last year,s comparable quarter. ... over last year,s comparable quarter. ...

... Separate Research Confirms Part D Seniors Also Enjoy Broad ... Pharmaceutical Care,Management Association (PCMA) issued the following statement on ... drug benefit is lower over the,next ten years than ... saving money without sacrificing beneficiaries,choice of prescription drugs. New ...

... of its ongoing efforts to do whatever it takes ... for Parkinson,s disease, The Michael J. Fox Foundation for ... total funding to four industry teams seeking to push ... awards were granted under MJFF,s Therapeutics Development Initiative (TDI) ...

Ford Motor Company Fund Continues Longtime Support to Cancer Care St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards Anti-parasite drug may provide new way to attack HIV Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 CMS: Part D Costs $117 Billion Lower Than Expected Michael J. Fox Foundation awards up to $3 million to industry teams

(Date:5/21/2013)... Calif. , May 21, 2013 STAAR ... developer, manufacturer and marketer of minimally invasive ophthalmic products, ... investor conferences to review the Company,s recent financial results ... STAAR Surgical will present at the 38 th ... Boston at the Westin Waterfront Hotel ...

(Date:5/21/2013)... , May 21, 2013 RxAlly , ... nationwide, announces today the publication of a white ... Health Care System. The white paper highlights an ... and seeks public engagement to avert strains on ... Care refers to a range of individually-tailored, pharmacist-provided ...

(Date:5/20/2013)... , May 20, 2013 Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the diagnosis ... announced it will highlight its efforts to expand research ... Flow Reserve (FFR) and iFR ® (Instant Wave-Free ... presentations and events at EuroPCR 2013 in ...

Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2 RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2 RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4

[0] STAAR Surgical To Present At Upcoming Investor Conferences [0] RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care [0] Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013

... Study at the Annual Scientific Meeting of ... the American College of Rheumatology, ... cost-utility study supporting the adoption of EUFLEXXA(TM) (1%,sodium hyaluronate) intra-articular ... osteoarthritis (OA) of the knee at the American,College of Rheumatology,s ...

... Sustained and Dose-Dependent in Sub-Analysis of Phase II ... ... SCH 530348 (TRA), the,novel investigational antiplatelet agent in development by ... inhibitor of platelet,aggregation in a sub-analysis of the Thrombin Receptor Antagonist ...

Cached Medicine Technology:Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 2 Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 3 Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 4 SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2 SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3 SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4 SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5 SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6 SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7

Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients

...

Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...

... product designed for LASIK surgery and other ... the corneal interface and/or stromal bed. Flattened ... and helps elevate the flap edge. Multiple ... G (.40 x 22mm). Angled 90 degrees, ...

... LASIK surgery and other types of ... corneal interface and/or stromal bed. Flattened ... flap and helps elevate the flap ... 23G x 7/8in (.60 x 22mm) ...

Medicine Products:

Hydrodissector - Daya Irrigating Cystotome - Reverse Lasik Irrigator - Probst Lasik Spatula/Irrigator